Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2

被引：1
|
作者：
Lu, J. [1 ]
Blakely, C. M. [2 ]
Barve, M. [3 ]
Chung, C. H. [4 ]
Waqar, S. N. [5 ]
Hu, X. [6 ]
Delord, J-P. [7 ]
Krzakowski, M. J. [8 ]
Yonemori, K. [9 ]
Chen, D. T. [10 ]
Klingbiel, D. [11 ]
Heinzmann, S. [12 ]
Le Tourneau, C. [13 ]
机构：
[1] USC Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA USA
[2] Univ Calif San Francisco, Dept Med, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94143 USA
[3] Mary Crowley Canc Res Ctr, Dallas, TX USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Head & Neck Endocrine Oncol, Tampa, MD USA
[5] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[6] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[7] Inst Univ Canc, Clin Res Unit, Toulouse, Haute Garonne, France
[8] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Lung Canc & Thorac Tumors, Warsaw, Poland
[9] Natl Canc Ctr, Dept Med Oncol, Tokyo, Japan
[10] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[11] F Hoffmann La Roche Ltd, Pharma Dev Data Sci, Data & Stat Sci, Basel, Switzerland
[12] F Hoffmann La Roche Ltd, Prod Dev & Med Affairs, Data & Stat Sci, Basel, Switzerland
[13] Paris Saclay Univ, Inst Curie, Dept Drug Dev & Innovat, Paris, France
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.192
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
173P
引用
收藏
页码：S204 / S205
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer
    Lu, Janice
    Blakely, Collin M.
    Le Tourneau, Christophe
    Waqar, Saiama N.
    Bauer, Todd M.
    de Braud, Filippo
    Hong, David S.
    Spira, Alexander
    Tan, Tira
    McCallum, Samuel
    Osborne, Stuart
    Simmons, Brian
    Barve, Minal
    CANCER RESEARCH, 2021, 81 (04)
  • [2] Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Demetri, G. D.
    Paz-Ares, L.
    Farago, A. F.
    Liu, S. V.
    Chawla, S. P.
    Tosi, D.
    Kim, E. S.
    Blakely, C.
    Krauss, J. C.
    Sigal, D.
    Bazhenova, L.
    John, T.
    Besse, B.
    Wolf, J.
    Seto, T.
    Chow-Maneval, E.
    Multani, P. S.
    Johnson, A. D.
    Simmons, B.
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] Updated efficacy and safety of entrectinib in patients (pts) with NTRK fusion-positive (NTRK-fp) NSCLC
    Cho, B. C.
    Chiu, C-H.
    Massarelli, E.
    Chawla, S. P.
    Buchschacher, G. L., Jr.
    Goto, K.
    Kim, S-W.
    Overbeck, T. R.
    Loong, H. H. F.
    Chee, C. E.
    Garrido, P.
    Heinzmann, S.
    Pitcher, B.
    John, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S82 - S83
  • [4] Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study
    Conley, A. P.
    Demetri, G. D.
    Doebele, R. C.
    Drilon, A.
    Paz-Ares, L.
    Cassier, P.
    Siena, S.
    Ahn, M-J.
    Buchschacher, G. L., Jr.
    Seto, T.
    Chee, C. E.
    Krzakowski, M.
    Ou, S-H. I.
    Grohe, C.
    Zagonel, V.
    Spira, A.
    Cheng, A.
    Kapre, A.
    Piault, E.
    Rolfo, C. D.
    ANNALS OF ONCOLOGY, 2020, 31 : S471 - S472
  • [5] Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Drilon, A.
    Paz-Ares, L.
    Doebele, R. C.
    Farago, A. F.
    Liu, S. V.
    Chawla, S. P.
    Tosi, D.
    Blakely, C. M.
    Krauss, J. C.
    Bazhenova, L.
    John, T.
    Besse, B.
    Wolf, J.
    Seto, T.
    Cho, B. C.
    Rolfo, C.
    Osborne, S.
    Aziez, A.
    Demetri, G. D.
    ANNALS OF ONCOLOGY, 2020, 31 : S474 - S475
  • [6] Updated Efficacy and Safety of Entrectinib in Patients (PTS) with NTRK Fusion-Positive (NTRK plus ) Tumors: Integrated Analysis of STARTRK-2, STARTRK-1, and ALKA-372-001
    Folprecht, Gunnar
    Rolfo, Christian
    Dziadziuszko, Rafal
    Doebele, Robert
    Demetri, George
    Simmons, Brian
    Huang, Xinhui
    Pitcher, Bethany
    Paz-Ares, Luis
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 216 - 217
  • [7] Entrectinib in NTRK fusion-positive breast cancer: integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001
    Springfeld, C.
    Blakely, C.
    Le Tourneau, C.
    Lu, J.
    Waqar, S. N.
    Huang, X.
    Day, B-M
    Simmons, B.
    Barve, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 160 - 160
  • [8] Entrectinib in NTRK fusion-positive breast cancer: Integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001
    Blakely, Collin
    Le Tourneau, Christophe
    Lu, Janice
    Waqar, Saiama N.
    Huang, Xinhui
    Day, Bannmo
    Simmons, Brian
    Barve, Minal
    CANCER RESEARCH, 2020, 80 (04)
  • [9] Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours
    Bazhenova, L.
    Liu, S. V.
    Lin, J. J.
    Lu, S.
    Drilon, A.
    Chawla, S. P.
    Fakih, M.
    Krzakowski, M.
    Paz-Ares, L.
    Blakely, C.
    Buchschacher, G. L., Jr.
    Cassier, P.
    Fan, Y.
    Folprecht, G.
    McCallum, S.
    Pitcher, B.
    Chen, D.
    Freund, R.
    Springfeld, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S598 - S599
  • [10] Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.
    Krzakowski, Maciej Jerzy
    Lu, Shun
    Cousin, Sophie
    Smit, Egbert F.
    Springfeld, Christoph
    Goto, Koichi
    Garrido, Pilar
    Chung, Christine H.
    Lin, Jessica Jiyeong
    Bray, Victoria J.
    Pitcher, Bethany
    Zeuner, Harald
    Patel, Siddhartha
    Bordogna, Walter
    Gelderblom, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345